{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["333(8)"],"submitter":["Chen L"],"pubmed_abstract":["<h4>Importance</h4>Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy. Camrelizumab, an anti-PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer.<h4>Objective</h4>To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with early or locally advanced triple-negative breast cancer.<h4>Design, setting, and participants</h4>This randomized, double-blind, phase 3 trial enrolled patients from 40 hospit"],"journal":["JAMA"],"pagination":["673-681"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11862970"],"repository":["biostudies-literature"],"pubmed_title":["Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial."],"pmcid":["PMC11862970"],"pubmed_authors":["Ouyang Q","Zhang H","Ren Y","Ma X","Wu F","Wang K","Liu Y","Yao Y","Wang S","Fan L","Qu X","Shen Y","Wang Z","Sun J","Zhang A","Wei L","Yang H","Pang D","Li H","Qian J","Chen L","Nie J","Cao SW","Zha X","Li Z","Wu SY","Shao ZM","Jiang A","Zhu X","Ouyang Z","Lei R","Fu P"],"additional_accession":[]},"is_claimable":false,"name":"Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.","description":"<h4>Importance</h4>Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy. Camrelizumab, an anti-PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer.<h4>Objective</h4>To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with early or locally advanced triple-negative breast cancer.<h4>Design, setting, and participants</h4>This randomized, double-blind, phase 3 trial enrolled patients from 40 hospit","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-03T06:42:23.504Z","creation":"2026-04-25T03:22:05.564Z"},"accession":"S-EPMC11862970","cross_references":{"pubmed":["39671272"],"doi":["10.1001/jama.2024.23560"]}}